Altimmune

next step ladder climb succeed win
Biotech

Altimmune eyes phase 3 MASH trial as weight loss deepens

Patients on the top dose of the GLP-1/glucagon dual receptor agonist continued to lose weight and improve on noninvasive measures of liver fibrosis.
Nick Paul Taylor Dec 19, 2025 8:30am
parachute sun mountain sunrise

Yet another CDER leadership shake-up—Chutes & Ladders

Dec 5, 2025 8:30am
Parachute over a mountain in Switzerland

GSK chief steps down in stunning move—Chutes & Ladders

Oct 3, 2025 8:30am
Liver

Altimmune stock sinks on mixed ph. 2 MASH results for GLP-1 drug

Jun 26, 2025 8:41am
weigh scale goliath outweigh balance bigger smaller even

Altimmune touts 'best-in-class' lean mass data in weight loss

Jun 23, 2024 1:45pm
stop shut down close end button

Altimmune bails on hepatitis B after phase 2 data disappoint

Mar 27, 2024 7:57am